Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava.

There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation. 

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial both tor the “forgotten” valve alone or in combination with the mitral valve. 

The study looked at 122 patients from the TriValve registry receiving combined transcatheter mitral plus tricuspid valve edge-to-edge repair (TMTVR) and 106 from the TRAMI registry receiving transcatheter mitral valve edge-to-edge repair (TMVR). They also presented severe tricuspid regurgitation. 

Mean age was 77; those receiving TMTVR were mostly women, had less severe left ventricular function deterioration <30% (18% vs. 39.4% p<0.001), end-diastole diameter (54 mm vs. 59 mm; p = 0.007), atrial fibrillation (68.7% vs. 55.7%; p= 0.029) and cardiac failure functional class IV (32.8% vs. 18.9%; p=0.013). In addition, glomerular filtration was lower.


Read also: Impella and Adverse Events.


EuroSCORE in the TRAMI group was 26.2% and in the TriValve group was 12.1%. Tricuspid annulus dilation was 47±8 mm in the TriValve group.

Procedural success in the mitral valve was similar, and was 81% in the tricuspid. In patients undergoing TMTVR, procedure duration prolonged 50 minutes. There were no differences in hospital evolution.


Read also: ACC Recommendations against the New Coronavirus.


At one-year follow-up, mortality was higher in TMVR patients (34% vs. 16.1% p=0.035), with no differences functional class improvement, which was significant. 

Conclusion

Joint treatment of both valves was associated to better survival vs. isolated mitral valve treatment in patients with severe mitral and tricuspid regurgitation. More randomized studies are necessary to confirm these results. 

Courtesy of Dr. Carlos Fava.

Original title: Combined Tricuspid and Mitral VersusIsolated Mitral Valve Repair for Severe Mitral and Tricuspid Regurgitation An Analysis From the TriValve and TRAMI Registries.

Reference: Michael Mehr, et al J Am Coll cardiol Intev 2020;13:543-50.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...